🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Recruitingn/aAges 14 Years - 80 YearsAllFujian Medical University
NCT07419932 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 14 years at enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). * LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board. * For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team. * Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Normal function of major organs. * Written informed consent obtained. Exclusion Criteria: * Patients who refuse tumor tissue biopsy or surgery. * Prior thyroid or major neck surgery. * History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan. * Concurrent active malignancies. * Uncontrolled systemic diseases, including diabetes, hypertension, etc. * Pregnancy or breastfeeding.
💊

What it tests

  • Multitarget Tyrosine Kinase Inhibitors
  • BRAF inhibitor dabrafenib and MEK inhibitor trametinib
  • RET Inhibitor
  • PD(L)-1 inhibitor
  • Biopsy
📍

Where

1 site
Fujian Medical University Union Hospital
Fuzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy